[HTML][HTML] Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
Q Wu, W Qian, X Sun, S Jiang - Journal of hematology & oncology, 2022 - Springer
Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …
[HTML][HTML] Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)
L Huang, S Jiang, Y Shi - Journal of hematology & oncology, 2020 - Springer
Tyrosine kinases are implicated in tumorigenesis and progression, and have emerged as
major targets for drug discovery. Tyrosine kinase inhibitors (TKIs) inhibit corresponding …
major targets for drug discovery. Tyrosine kinase inhibitors (TKIs) inhibit corresponding …
Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer
The cornerstone of treatment for advanced ALK-positive lung cancer is sequential therapy
with increasingly potent and selective ALK inhibitors. The third-generation ALK inhibitor …
with increasingly potent and selective ALK inhibitors. The third-generation ALK inhibitor …
[HTML][HTML] Personalized therapy for lung cancer: striking a moving target
S Pakkala, SS Ramalingam - JCI insight, 2018 - ncbi.nlm.nih.gov
Molecular targeted therapy heralded a new era for the treatment of patients with oncogene-
driven advanced-stage non–small-cell lung cancer (NSCLC). Molecular testing at the time of …
driven advanced-stage non–small-cell lung cancer (NSCLC). Molecular testing at the time of …
[HTML][HTML] The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC)
Lung cancer is the leading cause of death by cancer in North America. A decade ago,
genomic rearrangements in the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase …
genomic rearrangements in the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase …
[HTML][HTML] Emerging therapies for non-small cell lung cancer
Recent advances in the field of novel anticancer agents prolong patients' survival and show
a promising future. Tyrosine kinase inhibitors and immunotherapy for lung cancer are the …
a promising future. Tyrosine kinase inhibitors and immunotherapy for lung cancer are the …
Serial profiling of circulating tumor DNA identifies dynamic evolution of clinically actionable genomic alterations in high-risk neuroblastoma
KR Bosse, AM Giudice, MV Lane, B McIntyre… - Cancer discovery, 2022 - AACR
Neuroblastoma evolution, heterogeneity, and resistance remain inadequately defined,
suggesting a role for circulating tumor DNA (ctDNA) sequencing. To define the utility of …
suggesting a role for circulating tumor DNA (ctDNA) sequencing. To define the utility of …
ALK fusion partners impact response to ALK inhibition: differential effects on sensitivity, cellular phenotypes, and biochemical properties
MA Childress, SM Himmelberg, H Chen, W Deng… - Molecular Cancer …, 2018 - AACR
Oncogenic tyrosine kinase fusions involving the anaplastic lymphoma kinase (ALK) are
detected in numerous tumor types. Although more than 30 distinct 5′ fusion partner genes …
detected in numerous tumor types. Although more than 30 distinct 5′ fusion partner genes …
On-target resistance to the mutant-selective EGFR inhibitor osimertinib can develop in an allele-specific manner dependent on the original EGFR-activating mutation
Purpose: The third-generation EGFR inhibitor, osimertinib, is the first mutant-selective
inhibitor that has received regulatory approval for the treatment of patients with EGFR …
inhibitor that has received regulatory approval for the treatment of patients with EGFR …
[HTML][HTML] Non-small-cell lung cancer: how to manage ALK-, ROS1-and NTRK-rearranged disease
Oncogene addiction in non-small-cell lung cancer (NSCLC) has profound diagnostic and
therapeutic implications. ALK, ROS1 and NTRK rearrangements are found in about 2–7%, 1 …
therapeutic implications. ALK, ROS1 and NTRK rearrangements are found in about 2–7%, 1 …